Skip to main content
CriticalFDAfda-F-0631-2023UNDECLARED ALLERGEN

IWATSUKASEIKA Ajishirabe Rice Crackers UPC: 4901037117746 Made in Japan

⚠ Critical Alert — Stop Using Immediately

This product has been flagged with severe risks (undeclared allergen). Stop using it now and contact the brand or FDA for a refund, repair, or replacement.

Units Affected
897
Recall Date
February 10, 2023
Issuing Agency
Hazard
Undeclared Allergen

FDA Recall Notice

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-0631-2023.

The allergen of wheat was not declared on the label.

Corrective Action (per FDA)

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-0631-2023.

Recall terminated by FDA.

✅ What you should do

  1. Stop using the product if you own it.
  2. Check the model number, lot code, or sell-by date against the recall notice above.
  3. Contact Daiso California Warehouse or the retailer where you bought it for a refund, replacement, or repair.
  4. For the most current official instructions, visit the FDA recall page.
  5. If you've been hurt by this product, report the incident to FDA.

Consumer Contact (per FDA)

Source: U.S. Food and Drug Administration (FDA) — official FDA notice for recall FDA-F-0631-2023.

DAISO CALIFORNIA WAREHOUSE

FDA

About the U.S. Food and Drug Administration

The FDA regulates drugs, medical devices, food, cosmetics, and tobacco. Adverse event reports and recall notices are the main public safety signal.

Visit FDA.gov →

📣 Report a food, supplement, or cosmetic problem to the FDA

If you had a reaction, found contamination, or experienced a labeling problem with this product, report it to the FDA. The agency uses consumer reports to track emerging safety signals and trigger recalls.

How to report to FDAFile a report at FDA

Daiso California Warehouse Recall FAQ

Daiso California Warehouse is the subject of a bakery & grains safety report: IWATSUKASEIKA Ajishirabe Rice Crackers UPC: 4901037117746 Made in Japan. The notice was published on February 10, 2023 by the U.S. Food and Drug Administration (FDA). Approximately 897 units are potentially affected.